123 results on '"Totrov M"'
Search Results
2. P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
- Author
-
Wang S, Seaman MS, Krachmarov C, Pinter A, Totrov M, Gorny MK, Jiang X, Cohen S, Hioe C, Cardozo T, Kong X, Zolla-Pazner S, and Lu S
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2009
- Full Text
- View/download PDF
3. Spatial chemical distance based on atomic property fields
- Author
-
Grigoryan, A. V., Kufareva, I., Totrov, M., and Abagyan, R. A.
- Subjects
Chemistry ,Computer Applications in Chemistry ,Animal Anatomy / Morphology / Histology ,Physical Chemistry ,Chemical distance ,Chemical similarity ,Quantitative structure-property relationship ,Internal coordinates mechanics (ICM) ,Atomic property fields (APF) ,Spatial alignment - Abstract
Similarity of compound chemical structures often leads to close pharmacological profiles, including binding to the same protein targets. The opposite, however, is not always true, as distinct chemical scaffolds can exhibit similar pharmacology as well. Therefore, relying on chemical similarity to known binders in search for novel chemicals targeting the same protein artificially narrows down the results and makes lead hopping impossible. In this study we attempt to design a compound similarity/distance measure that better captures structural aspects of their pharmacology and molecular interactions. The measure is based on our recently published method for compound spatial alignment with atomic property fields as a generalized 3D pharmacophoric potential. We optimized contributions of different atomic properties for better discrimination of compound pairs with the same pharmacology from those with different pharmacology using Partial Least Squares regression. Our proposed similarity measure was then tested for its ability to discriminate pharmacologically similar pairs from decoys on a large diverse dataset of 115 protein–ligand complexes. Compared to 2D Tanimoto and Shape Tanimoto approaches, our new approach led to improvement in the area under the receiver operating characteristic curve values in 66 and 58% of domains respectively. The improvement was particularly high for the previously problematic cases (weak performance of the 2D Tanimoto and Shape Tanimoto measures) with original AUC values below 0.8. In fact for these cases we obtained improvement in 86% of domains compare to 2D Tanimoto measure and 85% compare to Shape Tanimoto measure. The proposed spatial chemical distance measure can be used in virtual ligand screening.
- Published
- 2010
4. Biological Studies and Target Engagement of the 2-C-Methyl-D-Erythritol 4-Phosphate Cytidylyltransferase (IspD)-Targeting Antimalarial Agent (1R,3S)-MMV008138 and Analogs
- Author
-
Ghavami M, Merino E, Yao Z, Elahi R, Simpson M, Fernandez-Murga M, Butler J, Casasanta M, Krai P, Totrov M, Slade D, Carlier P, and Cassera M
- Subjects
structure-activity studies ,Plasmodium ,IspD ,malaria ,MMV008138 ,MEP pathway - Abstract
Malaria continues to be one of the deadliest diseases worldwide, and the emergence of drug resistance parasites is a constant threat. Plasmodium parasites utilize the methylerythritol phosphate (MEP) pathway to synthesize isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are essential for parasite growth. Previously, we and others identified that the Malaria Box compound MMV008138 targets the apicoplast and that parasite growth inhibition by this compound can be reversed by supplementation of IPP. Further work has revealed that MMV008138 targets the enzyme 2-C-methyl-n-erythritol 4-phosphate cytidylyltransferase (IspD) in the MEP pathway, which converts MEP and cytidine triphosphate (CTP) to cytidinediphosphate methylerythritol (CDP-ME) and pyrophosphate. In this work, we sought to gain insight into the structure-activity relationships by probing the ability of MMV008138 analogs to inhibit PfIspD recombinant enzyme. Here, we report PfIspD inhibition data for fosmidomycin (FOS) and 19 previously disclosed analogs and report parasite growth and PfIspD inhibition data for 27 new analogs of MMV008138. In addition, we show that MMV008138 does not target the recently characterized human IspD, reinforcing MMV008138 as a prototype of a new class of species-selective IspD-targeting antimalarial agents.
- Published
- 2018
5. Crystal structure of Fab of rhesus mAb 2.5B specific for quaternary neutralizing epitope of HIV-1 gp120
- Author
-
Spurrier, B., primary, Sampson, J., additional, Totrov, M., additional, Li, H., additional, O'Neal, T., additional, William, C., additional, Robinson, J., additional, Gorny, M.K., additional, Zolla-Pazner, S., additional, and Kong, X.P., additional
- Published
- 2011
- Full Text
- View/download PDF
6. Crystal structure of Fab of human mAb 2909 specific for quaternary neutralizing epitope of HIV-1 gp120
- Author
-
Spurrier, B., primary, Sampson, J., additional, Totrov, M., additional, Li, H., additional, O'Neal, T., additional, William, C., additional, Robinson, J., additional, Gorny, M.K., additional, Zolla-Pazner, S., additional, and Kong, X.P., additional
- Published
- 2011
- Full Text
- View/download PDF
7. P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold
- Author
-
Totrov, M, primary, Jiang, X, additional, Kong, X, additional, Cohen, S, additional, Krachmarov, C, additional, Williams, C, additional, Cardozo, T, additional, Gorny, M, additional, Wang, S, additional, Lu, S, additional, Pinter, A, additional, and Zolla-Pazner, S, additional
- Published
- 2009
- Full Text
- View/download PDF
8. P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
- Author
-
Zolla-Pazner, S, primary, Kong, X, additional, Cardozo, T, additional, Hioe, C, additional, Cohen, S, additional, Jiang, X, additional, Gorny, MK, additional, Totrov, M, additional, Pinter, A, additional, Krachmarov, C, additional, Seaman, MS, additional, Wang, S, additional, and Lu, S, additional
- Published
- 2009
- Full Text
- View/download PDF
9. P04-42. Molecular design of a mimotope that preserves conserved structural elements of the HIV-1 V3 crown
- Author
-
Jiang, X, primary, Totrov, M, additional, Sampson, J, additional, Williams, C, additional, Gorny, MK, additional, Zollla-Pazner, S, additional, and Kong, X, additional
- Published
- 2009
- Full Text
- View/download PDF
10. Molecular docking programs successfully predict the binding of a β-lactamase inhibitory protein to TEM-1 β-lactamase
- Author
-
Strynadka, N.C.J., primary, Eisenstein, M., additional, Katchalski-Katzir, E., additional, Shoichet, B.K., additional, Kuntz, I.D., additional, Abagyan, R., additional, Totrov, M., additional, Janin, J., additional, Cherfils, J., additional, Zimmerman, F., additional, Olson, A., additional, Duncan, B., additional, Rao, M., additional, Jackson, R., additional, Sternberg, M., additional, and James, M.N.G., additional
- Published
- 1996
- Full Text
- View/download PDF
11. A Novel Class of Inhibitors of Peptide Deformylase Discovered through High-Throughput Screening and Virtual Ligand Screening
- Author
-
Howard, M. H., Cenizal, T., Gutteridge, S., Hanna, W. S., Tao, Y., Totrov, M., Wittenbach, V. A., and Zheng, Y.-j.
- Abstract
Peptide deformylase (PDF) has been identified as a promising antibacterial and herbicide target. A structurally novel class of inhibitors containing a 2-thioxo-thiazolidin-4-one heterocycle substituted by an arylidene group at the 5-position and a hexanoic acid side chain at the 3-position was discovered independently via high-throughput screening and virtual ligand screening. Data mining and analogue synthesis established a structure−activity relationship for the side chain region that is consistent with the docked structure.
- Published
- 2004
12. Nuclear Hormone Receptor Targeted Virtual Screening
- Author
-
Schapira, M., Abagyan, R., and Totrov, M.
- Abstract
Virtual library screening (VLS) is emerging as a valuable drug lead discovery tool. ICM-VLS implementation of this technology was evaluated on a benchmark set of nuclear hormone receptors (NRs), an important therapeutic target family. Over 5000 structurally diverse compounds, including 78 known NR ligands, were screened against 18 crystal structures and one computer model of 10 NR ligand binding domains in their active or inactive states. The results confirm the ability of the VLS method to generate highly focused subsets of the input chemical library, enriched 33- to 100-fold for all but one receptor studied. However, receptor flexibility remains to be fully addressed, and the choice of the specific conformation used for screening may determine the success of the exercise. We observe that for a particular ligand VLS can often identify the correct target within the receptor family, although the technology is unable to reliably discriminate between the closely related receptor isoforms. Additionally, our results suggest that VLS may be applied successfully without an experimental structure of the receptor by using a homology model. These data represent a realistic snapshot of the state-of-the-art of NR-targeted VLS and define the recent progress and the remaining limitations of the technology.
- Published
- 2003
13. Computer applications for prediction of protein-protein interactions and rational drug design
- Author
-
Grosdidier, S., Totrov, M., and Juan Fernandez-Recio
14. INTERACTIVE 3D VISUALISATIONS OF PROTEIN STRUCTURES TO AID THE STUDY OF INBORN ERRORS OF METABOLISM
- Author
-
Wen Hwa Lee, Raush, E., Totrov, M., Abagyan, R., Marsden, B. D., Oppermann, U., and Yue, W. W.
15. Ligand binding site superposition and comparison based on Atomic Property Fields: identification of distant homologues, convergent evolution and PDB-wide clustering of binding sites
- Author
-
Totrov Maxim
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Biology (General) ,QH301-705.5 - Abstract
Abstract A new binding site comparison algorithm using optimal superposition of the continuous pharmacophoric property distributions is reported. The method demonstrates high sensitivity in discovering both, distantly homologous and convergent binding sites. Good quality of superposition is also observed on multiple examples. Using the new approach, a measure of site similarity is derived and applied to clustering of ligand binding pockets in PDB.
- Published
- 2011
- Full Text
- View/download PDF
16. The use of the magnetic field effect for studying a chemiluminescent chemical reaction in aqueous solution. Reaction rate constants and lifetimes intermediate molecules
- Author
-
Triebel, M. M., Totrov, M. M., Zorinyants, G. E., and Frankevich, E. L.
- Published
- 1993
- Full Text
- View/download PDF
17. Phase-on-frequency characteristics of the magnetic field effect for studying the mechanism of the branching chemiluminescent reaction of luminol
- Author
-
Triebel, M. M., Morozov, A. K., Totrov, M. M., and Zorinyants, G. E.
- Published
- 1993
- Full Text
- View/download PDF
18. Efficient Generation of Conformer Ensembles Using Internal Coordinates and a Generative Directional Graph Convolution Neural Network.
- Author
-
Raush E, Abagyan R, and Totrov M
- Abstract
We present a neural-network-based high-throughput molecular conformer-generation algorithm. A chemical graph-convolutional network is trained to predict low-energy conformers in internal coordinate representation (bond lengths, bond, and torsion angles), starting from two-dimensional (2D) chemical topology. Generative neural network (NN) architecture performs denoising from torsion space, producing conformer ensembles with populations that are well correlated with torsion energy profiles. Short force-field-based energy minimization is applied to refine final conformers. All computation-intensive stages of the algorithm are GPU-optimized. The procedure (termed GINGER) is benchmarked on a commonly used test set of bioactive three-dimensional (3D) conformers from the PDB. We demonstrate highly competitive results in conformer recovery and throughput rates suitable for giga-scale compound library processing. A web server that allows interactive conformer ensemble generation by GINGER and their viewing is made freely available at https://www.molsoft.com/gingerdemo.html.
- Published
- 2024
- Full Text
- View/download PDF
19. Software and Databases for Protein-Protein Docking.
- Author
-
Jarończyk M, Abagyan R, and Totrov M
- Subjects
- Computational Biology methods, Protein Binding, Humans, Software, Databases, Protein, Molecular Docking Simulation, Protein Interaction Mapping methods, Proteins chemistry, Proteins metabolism
- Abstract
Protein-protein interactions (PPIs) provide valuable insights for understanding the principles of biological systems and for elucidating causes of incurable diseases. One of the techniques used for computational prediction of PPIs is protein-protein docking calculations, and a variety of software has been developed. This chapter is a summary of software and databases used for protein-protein docking., (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
20. In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales .
- Author
-
Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Totrov M, Loutit J, and Dudley M
- Subjects
- Carbapenems pharmacology, beta Lactam Antibiotics, Cefepime, Lactams, beta-Lactamases, Serine, Microbial Sensitivity Tests, Azabicyclo Compounds pharmacology, beta-Lactamase Inhibitors pharmacology, Anti-Bacterial Agents pharmacology
- Abstract
Recently, several β-lactam (BL)/β-lactamase inhibitor (BLI) combinations have entered clinical testing or have been marketed for use, but limited direct comparative studies of their in vitro activity exist. Xeruborbactam (XER, also known as QPX7728), which is undergoing clinical development, is a cyclic boronate BLI with potent inhibitory activity against serine (serine β-lactamase) and metallo-β-lactamases (MBLs). The objectives of this study were (i) to compare the potency and spectrum of β-lactamase inhibition by various BLIs in biochemical assays using purified β-lactamases and in microbiological assays using the panel of laboratory strains expressing diverse serine and metallo-β-lactamases and (ii) to compare the in vitro potency of XER in combination with multiple β-lactam antibiotics to that of other BL/BLI combinations in head-to-head testing against recent isolates of carbapenem-resistant Enterobacterales (CRE). Minimal inhibitory concentrations (MICs) of XER combinations were tested with XER at fixed 4 or 8 µg/mL, and MIC testing was conducted in a blinded fashion using Clinical and Laboratory Standards Institute reference methods. Xeruborbactam and taniborbactam (TAN) were the only BLIs that inhibited clinically important MBLs. The spectrum of activity of xeruborbactam included several MBLs identified in Enterobacterales, e.g., and various IMP enzymes and NDM-9 that were not inhibited by taniborbactam. Xeruborbactam potency against the majority of purified β-lactamases was the highest in comparison with other BLIs. Meropenem-xeruborbactam (MEM-XER, fixed 8 µg/mL) was the most potent combination against MBL-negative CRE with MIC
90 values of 0.125 µg/mL. MEM-XER and cefepime-taniborbactam (FEP-TAN) were the only BL/BLIs with activity against MBL-producing CREs; with MEM-XER (MIC90 of 1 µg/mL) being at least 16-fold more potent than FEP-TAN (MIC90 of 16 µg/mL). MEM-XER MIC values were ≤8 µg/mL for >90% of CRE, including both MBL-negative and MBL-positive isolates, with FEP-TAN MIC of >8 µg/mL. Xeruborbactam also significantly enhanced potency of other β-lactam antibiotics, including cefepime, ceftolozane, ceftriaxone, aztreonam, piperacillin, and ertapenem, against clinical isolates of Enterobacterales that carried various class A, class C, and class D extended-spectrum β-lactamases and carbapenem-resistant Enterobacterales , including metallo-β-lactamase-producing isolates. These results strongly support further clinical development of xeruborbactam combinations., Competing Interests: The authors declare no conflict of interest.- Published
- 2023
- Full Text
- View/download PDF
21. Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1.
- Author
-
Hioe CE, Liu X, Banin AN, Heindel DW, Klingler JR, Rao PG, Luo CC, Jiang X, Pandey S, Ordonez T, Barnette P, Totrov M, Zhu J, Na das A, Zolla-Pazner S, Upadhyay C, Shen X, Kong XP, and Hessell AJ
- Abstract
[This corrects the article DOI: 10.3389/fimmu.2023.1271686.]., (Copyright © 2023 Hioe, Liu, Banin, Heindel, Klingler, Rao, Luo, Jiang, Pandey, Ordonez, Barnette, Totrov, Zhu, Na´das, Zolla-Pazner, Upadhyay, Shen, Kong and Hessell.)
- Published
- 2023
- Full Text
- View/download PDF
22. Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1.
- Author
-
Hioe CE, Liu X, Banin AN, Heindel DW, Klingler J, Rao PG, Luo CC, Jiang X, Pandey S, Ordonez T, Barnette P, Totrov M, Zhu J, Nádas A, Zolla-Pazner S, Upadhyay C, Shen X, Kong XP, and Hessell AJ
- Subjects
- Animals, Rabbits, HIV Antibodies, Antigen-Antibody Complex, Vaccination, Antibodies, Neutralizing, Epitopes, DNA, HIV Infections, HIV-1, Vaccines, DNA, HIV Seropositivity
- Abstract
Introduction: Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of HIV-1 isolates has been an arduous challenge., Objective: This study sought to test vaccines aimed to induce Abs against neutralizing epitopes at the V1V2 apex of HIV-1 envelope (Env)., Methods: Four groups of rabbits received a DNA vaccine expressing the V1V2 domain of the CRF01_AE A244 strain on a trimeric 2J9C scaffold (V1V2-2J9C) along with a protein vaccine consisting of an uncleaved prefusion-optimized A244 Env trimer with V3 truncation (UFO-BG.ΔV3) or a V1V2-2J9C protein and their respective immune complexes (ICs). These IC vaccines were made using 2158, a V1V2-specific monoclonal Ab (mAb), which binds the V2i epitope in the underbelly region of V1V2 while allosterically promoting the binding of broadly neutralizing mAb PG9 to its V2 apex epitope in vitro ., Results: Rabbit groups immunized with the DNA vaccine and uncomplexed or complexed UFO-BG.ΔV3 proteins (DNA/UFO-UC or IC) displayed similar profiles of Env- and V1V2-binding Abs but differed from the rabbits receiving the DNA vaccine and uncomplexed or complexed V1V2-2J9C proteins (DNA/V1V2-UC or IC), which generated more cross-reactive V1V2 Abs without detectable binding to gp120 or gp140 Env. Notably, the DNA/UFO-UC vaccine elicited neutralizing Abs against some heterologous tier 1 and tier 2 viruses from different clades, albeit at low titers and only in a fraction of animals, whereas the DNA/V1V2-UC or IC vaccines did not. In comparison with the DNA/UFO-UC group, the DNA/UFO-IC group showed a trend of higher neutralization against TH023.6 and a greater potency of V1V2-specific Ab-dependent cellular phagocytosis (ADCP) but failed to neutralize heterologous viruses., Conclusion: These data demonstrate the capacity of V1V2-2J9C-encoding DNA vaccine in combination with UFO-BG.ΔV3, but not V1V2-2J9C, protein vaccines, to elicit homologous and heterologous neutralizing activities in rabbits. The elicitation of neutralizing and ADCP activities was modulated by delivery of UFO-BG.ΔV3 complexed with V2i mAb 2158., Competing Interests: Author MT was employed by company Molsoft L.L.C. MT, XJ, X-PK, and SZ-P are inventors in the U.S. Patent 10,568,969 for the V1V2-2J9C construct. A provisional patent application is submitted for the UFO-BG.DeltaV3 construct; CEH and MT are listed as inventors in this application. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Hioe, Liu, Banin, Heindel, Klingler, Rao, Luo, Jiang, Pandey, Ordonez, Barnette, Totrov, Zhu, Nádas, Zolla-Pazner, Upadhyay, Shen, Kong and Hessell.)
- Published
- 2023
- Full Text
- View/download PDF
23. New boronate drugs and evolving NDM-mediated beta-lactam resistance.
- Author
-
Lomovskaya O, Tsivkovski R, Totrov M, Dressel D, Castanheira M, and Dudley M
- Subjects
- Amino Acid Substitution, Boronic Acids pharmacology, beta-Lactam Resistance genetics, beta-Lactamase Inhibitors pharmacology, Borinic Acids
- Abstract
Taniborbactam and xeruborbactam are dual serine-/metallo-beta-lactamase inhibitors (BLIs) based on a cyclic boronic acid pharmacophore that undergo clinical development. Recent report demonstrated that New Delhi metallo-beta-lactamase (NDM)-9 (differs from NDM-1 by a single amino acid substitution, E152K, evolved to overcome Zn (II) deprivation) is resistant to inhibition by taniborbactam constituting pre-existing taniborbactam resistance mechanism. Using microbiological and biochemical experiments, we show that xeruborbactam is capable of inhibiting NDM-9 and propose the structural basis for differences between two BLIs., Competing Interests: O.L., R.T., and M.D. are employees and shareholders of Qpex Biopharma, which is developing xeruborbactam.
- Published
- 2023
- Full Text
- View/download PDF
24. Graph-Convolutional Neural Net Model of the Statistical Torsion Profiles for Small Organic Molecules.
- Author
-
Raush E, Abagyan R, and Totrov M
- Subjects
- Crystallography, Databases, Factual, Neural Networks, Computer
- Abstract
We present a graph-convolutional neural network (GCNN)-based method for learning and prediction of statistical torsional profiles (STP) in small organic molecules based on the experimental X-ray structure data. A specialized GCNN torsion profile model is trained using the structures in the Crystallography Open Database (COD). The GCNN-STP model captures torsional preferences over a wide range of torsion rotor chemotypes and correctly predicts a variety of effects from the vicinal atoms and moieties. GCNN-STP statistical profiles also show good agreement with quantum chemically (DFT) calculated torsion energy profiles. Furthermore, we demonstrate the application of the GCNN-STP statistical profiles for conformer generation. A web server that allows interactive profile prediction and viewing is made freely available at https://www.molsoft.com/tortool.html.
- Published
- 2022
- Full Text
- View/download PDF
25. Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability.
- Author
-
Raja Reddy K, Totrov M, Lomovskaya O, Griffith DC, Tarazi Z, Clifton MC, and Hecker SJ
- Subjects
- Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Biological Availability, beta-Lactamases metabolism, Prodrugs pharmacology, beta-Lactamase Inhibitors chemistry, beta-Lactamase Inhibitors pharmacology
- Abstract
Early efforts to broaden the spectrum and potency of cyclic boronic acid β-lactamase inhibitor vaborbactam included a series of 7-membered ring boronates. Exploration of stereoisomers and incorporation of heteroatoms allowed identification of the all-carbon cyclic boronate with substituents trans as the preferred core structure, showing inhibition of Class A and C enzymes. Crystal structures of one analog bound to important β-lactamase enzymes were obtained. When isolated under acidic conditions, these compounds spontaneously formed a neutral cyclic anhydride (intramolecular prodrug) which was shown to have much-improved oral bioavailability (52-69%) compared to the ring-opened carboxylate salt (9%)., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. Enantiopure Benzofuran-2-carboxamides of 1-Aryltetrahydro-β-carbolines Are Potent Antimalarials In Vitro .
- Author
-
Almolhim H, Ding S, Butler JH, Bremers EK, Butschek GJ, Slebodnick C, Merino EF, Rizopoulos Z, Totrov M, Cassera MB, and Carlier PR
- Abstract
The tetrahydro-β-carboline scaffold has proven fertile ground for the discovery of antimalarial agents (e.g., MMV008138 ( 1 ) and cipargamin ( 2 )). Similarity searching of a publicly disclosed collection of antimalarial hits for molecules resembling 1 drew our attention to N2-acyl tetrahydro-β-carboline GNF-Pf-5009 ((±)- 3b ). Compound purchase, "analog by catalog", and independent synthesis of hits indicated the benzofuran-2-yl amide portion was required for in vitro efficacy against P. falciparum . Preparation of pure enantiomers demonstrated the pharmacological superiority of ( R )- 3b . Synthesis and evaluation of D- and F-ring substitution variants and benzofuran isosteres indicated a clear structure-activity relationship. Ultimately ( R )- 3b was tested in Plasmodium berghei -infected mice; unfavorable physicochemical properties may be responsible for the lack of oral efficacy., Competing Interests: The authors declare no competing financial interest., (© 2022 American Chemical Society.)
- Published
- 2022
- Full Text
- View/download PDF
27. Malaria Box-Inspired Discovery of N -Aminoalkyl-β-carboline-3-carboxamides, a Novel Orally Active Class of Antimalarials.
- Author
-
Mathew J, Ding S, Kunz KA, Stacy EE, Butler JH, Haney RS, Merino EF, Butschek GJ, Rizopoulos Z, Totrov M, Cassera MB, and Carlier PR
- Abstract
Virtual ligand screening of a publicly available database of antimalarial hits using a pharmacophore derived from antimalarial MMV008138 identified TCMDC-140230, a tetrahydro-β-carboline amide, as worthy of exploration. All four stereoisomers of this structure were synthesized, but none potently inhibited growth of the malaria parasite Plasmodium falciparum . Interestingly, 7e , a minor byproduct of these syntheses, proved to be potent in vitro against P. falciparum and was orally efficacious (40 mg/kg) in an in vivo mouse model of malaria., Competing Interests: The authors declare no competing financial interest., (© 2022 American Chemical Society.)
- Published
- 2022
- Full Text
- View/download PDF
28. Structural dissection of sequence recognition and catalytic mechanism of human LINE-1 endonuclease.
- Author
-
Miller I, Totrov M, Korotchkina L, Kazyulkin DN, Gudkov AV, and Korolev S
- Subjects
- Base Sequence, Binding Sites, Cloning, Molecular, Crystallography, X-Ray, DNA genetics, DNA metabolism, DNA Cleavage, DNA-(Apurinic or Apyrimidinic Site) Lyase genetics, DNA-(Apurinic or Apyrimidinic Site) Lyase metabolism, Deoxyribonuclease I genetics, Deoxyribonuclease I metabolism, Escherichia coli genetics, Escherichia coli metabolism, Gene Expression, Genetic Vectors chemistry, Genetic Vectors metabolism, Genome, Human, Genomic Instability, Humans, Models, Molecular, Nucleic Acid Conformation, Protein Binding, Protein Conformation, alpha-Helical, Protein Conformation, beta-Strand, Protein Interaction Domains and Motifs, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Substrate Specificity, Thermodynamics, DNA chemistry, DNA-(Apurinic or Apyrimidinic Site) Lyase chemistry, Deoxyribonuclease I chemistry
- Abstract
Long interspersed nuclear element-1 (L1) is an autonomous non-LTR retrotransposon comprising ∼20% of the human genome. L1 self-propagation causes genomic instability and is strongly associated with aging, cancer and other diseases. The endonuclease domain of L1's ORFp2 protein (L1-EN) initiates de novo L1 integration by nicking the consensus sequence 5'-TTTTT/AA-3'. In contrast, related nucleases including structurally conserved apurinic/apyrimidinic endonuclease 1 (APE1) are non-sequence specific. To investigate mechanisms underlying sequence recognition and catalysis by L1-EN, we solved crystal structures of L1-EN complexed with DNA substrates. This showed that conformational properties of the preferred sequence drive L1-EN's sequence-specificity and catalysis. Unlike APE1, L1-EN does not bend the DNA helix, but rather causes 'compression' near the cleavage site. This provides multiple advantages for L1-EN's role in retrotransposition including facilitating use of the nicked poly-T DNA strand as a primer for reverse transcription. We also observed two alternative conformations of the scissile bond phosphate, which allowed us to model distinct conformations for a nucleophilic attack and a transition state that are likely applicable to the entire family of nucleases. This work adds to our mechanistic understanding of L1-EN and related nucleases and should facilitate development of L1-EN inhibitors as potential anticancer and antiaging therapeutics., (© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2021
- Full Text
- View/download PDF
29. Retraction Note: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance.
- Author
-
Singh KS, Sharma R, Reddy PAN, Vonteddu P, Good M, Sundarrajan A, Choi H, Muthumani K, Kossenkov A, Goldman AR, Tang HY, Totrov M, Cassel J, Murphy ME, Somasundaram R, Herlyn M, Salvino JM, and Dotiwala F
- Published
- 2021
- Full Text
- View/download PDF
30. QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics.
- Author
-
Lomovskaya O, Tsivkovski R, Sun D, Reddy R, Totrov M, Hecker S, Griffith D, Loutit J, and Dudley M
- Abstract
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam). In this paper we provide the overview of the biochemical, structural and microbiological studies that were recently conducted with QPX7728. We show that QPX7728 is an ultra-broad-spectrum β-lactamase inhibitor with the broadest spectrum of inhibition reported to date in a single BLI molecule; in addition to potent inhibition of clinically important serine β-lactamases, including Class A and D carbapenemases from Enterobacterales and notably, diverse Class D carbapenemases from Acinetobacter, it also inhibits many metallo β-lactamases. Importantly, it is minimally affected by general intrinsic resistance mechanisms such as efflux and porin mutations that impede entry of drugs into gram-negative bacteria. QPX7728 combinations with several intravenous (IV) β-lactam antibiotics shows broad coverage of Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa , including strains that are resistant to other IV β-lactam-BLI combinations, e.g., ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and imipenem-relebactam that were recently approved for clinical use. Based on studies with P. aeruginosa , different partner β-lactams in combination with QPX7728 may be optimal for the coverage of susceptible organisms. This provides microbiological justification for a stand-alone BLI product for co-administration with different β-lactams. QPX7728 can also be delivered orally; thus, its ultra-broad β-lactamase inhibition spectrum and other features could be also applied to oral QPX7728-based combination products. Clinical development of QPX7728 has been initiated., Competing Interests: OL, RT, DS, RR, SH, DG, JL, and MD are employees and shareholders of Qpex Biopharma that is developing QPX7728. MT is an employee of Molsoft, LLC. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Lomovskaya, Tsivkovski, Sun, Reddy, Totrov, Hecker, Griffith, Loutit and Dudley.)
- Published
- 2021
- Full Text
- View/download PDF
31. IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance.
- Author
-
Singh KS, Sharma R, Reddy PAN, Vonteddu P, Good M, Sundarrajan A, Choi H, Muthumani K, Kossenkov A, Goldman AR, Tang HY, Totrov M, Cassel J, Murphy ME, Somasundaram R, Herlyn M, Salvino JM, and Dotiwala F
- Subjects
- Animals, Drug Resistance, Microbial, Drug Resistance, Multiple, Enzyme Inhibitors chemistry, Escherichia coli Proteins genetics, Escherichia coli Proteins metabolism, Female, Half-Life, Humans, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear microbiology, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Microbial Sensitivity Tests, Molecular Docking Simulation, Oxidoreductases deficiency, Oxidoreductases genetics, Oxidoreductases metabolism, Prodrugs pharmacokinetics, Prodrugs pharmacology, Substrate Specificity, Swine blood, T-Lymphocytes, Cytotoxic immunology, Drug Design, Enzyme Inhibitors pharmacology, Escherichia coli Proteins antagonists & inhibitors, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria immunology, Lymphocyte Activation drug effects, Microbial Viability drug effects, Oxidoreductases antagonists & inhibitors, T-Lymphocytes, Cytotoxic drug effects
- Abstract
Isoprenoids are vital for all organisms, in which they maintain membrane stability and support core functions such as respiration
1 . IspH, an enzyme in the methyl erythritol phosphate pathway of isoprenoid synthesis, is essential for Gram-negative bacteria, mycobacteria and apicomplexans2,3 . Its substrate, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), is not produced in metazoans, and in humans and other primates it activates cytotoxic Vγ9Vδ2 T cells at extremely low concentrations4-6 . Here we describe a class of IspH inhibitors and refine their potency to nanomolar levels through structure-guided analogue design. After modification of these compounds into prodrugs for delivery into bacteria, we show that they kill clinical isolates of several multidrug-resistant bacteria-including those from the genera Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella, Yersinia, Mycobacterium and Bacillus-yet are relatively non-toxic to mammalian cells. Proteomic analysis reveals that bacteria treated with these prodrugs resemble those after conditional IspH knockdown. Notably, these prodrugs also induce the expansion and activation of human Vγ9Vδ2 T cells in a humanized mouse model of bacterial infection. The prodrugs we describe here synergize the direct killing of bacteria with a simultaneous rapid immune response by cytotoxic γδ T cells, which may limit the increase of antibiotic-resistant bacterial populations.- Published
- 2021
- Full Text
- View/download PDF
32. In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii.
- Author
-
Nelson K, Rubio-Aparicio D, Tsivkovski R, Sun D, Totrov M, Dudley M, and Lomovskaya O
- Subjects
- Anti-Bacterial Agents pharmacology, Carbapenems pharmacology, Meropenem pharmacology, Microbial Sensitivity Tests, beta-Lactamase Inhibitors pharmacology, beta-Lactamases genetics, Acinetobacter baumannii genetics
- Abstract
QPX7728 is a recently discovered ultra-broad-spectrum beta-lactamase inhibitor (BLI) with potent inhibition of key serine and metallo-beta-lactamases. QPX7728 enhances the potency of many beta-lactams, including carbapenems, in beta-lactamase-producing Gram-negative bacteria, including Acinetobacter spp. The potency of meropenem alone and in combination with QPX7728 (1 to 16 μg/ml) was tested against 275 clinical isolates of Acinetobacter baumannii (carbapenem-resistant A. baumannii [CRAB]) collected worldwide that were highly resistant to carbapenems (MIC
50 and MIC90 for meropenem, 64 and >64 μg/ml). Addition of QPX7728 resulted in a marked concentration-dependent increase in meropenem potency, with the MIC90 of meropenem alone decreasing from >64 μg/ml to 8 and 4 μg/ml when tested with fixed concentrations of QPX7728 at 4 and 8 μg/ml, respectively. In order to identify the mechanisms that modulate the meropenem-QPX7728 MIC, the whole-genome sequences were determined for 135 isolates with a wide distribution of meropenem-QPX7728 MICs. This panel of strains included 116 strains producing OXA carbapenemases (71 OXA-23, 16 OXA-72, 16 OXA-24, 9 OXA-58, and 4 OXA-239), 5 strains producing NDM-1, one KPC-producing strain, and 13 strains that did not carry any known carbapenemases but were resistant to meropenem (MIC ≥ 4 μg/ml). Our analysis indicated that mutated PBP3 (with mutations localized in the vicinity of the substrate/inhibitor binding site) is the main factor that contributes to the reduction of meropenem-QPX7728 potency. Still, >90% of isolates that carried PBP3 mutations remained susceptible to ≤8 μg/ml of meropenem when tested with a fixed 4 to 8 μg/ml of QPX7728. In the absence of PBP3 mutations, the MICs of meropenem tested in combination with 4 to 8 μg/ml of QPX7728 did not exceed 8 μg/ml. In the presence of both PBP3 and efflux mutations, 84.6% of isolates were susceptible to ≤8 μg/ml of meropenem with 4 or 8 μg/ml of QPX7728. The combination of QPX7728 with meropenem against CRAB isolates with multiple resistance mechanisms has an attractive microbiological profile., (Copyright © 2020 American Society for Microbiology.)- Published
- 2020
- Full Text
- View/download PDF
33. Structural Basis and Binding Kinetics of Vaborbactam in Class A β-Lactamase Inhibition.
- Author
-
Pemberton OA, Tsivkovski R, Totrov M, Lomovskaya O, and Chen Y
- Subjects
- Boronic Acids, Kinetics, beta-Lactamase Inhibitors, Anti-Bacterial Agents pharmacology, beta-Lactamases genetics, beta-Lactamases metabolism
- Abstract
Class A β-lactamases are a major cause of β-lactam resistance in Gram-negative bacteria. The recently FDA-approved cyclic boronate vaborbactam is a reversible covalent inhibitor of class A β-lactamases, including CTX-M extended-spectrum β-lactamase and KPC carbapenemase, both frequently observed in the clinic. Intriguingly, vaborbactam displayed different binding kinetics and cell-based activity for these two enzymes, despite their similarity. A 1.0-Å crystal structure of CTX-M-14 demonstrated that two catalytic residues, K73 and E166, are positively charged and neutral, respectively. Meanwhile, a 1.25-Å crystal structure of KPC-2 revealed a more compact binding mode of vaborbactam versus CTX-M-14, as well as alternative conformations of W105. Together with kinetic analysis of W105 mutants, the structures demonstrate the influence of this residue and the unusual conformation of the β3 strand on the inactivation rate, as well as the stability of the reversible covalent bond with S70. Furthermore, studies of KPC-2 S130G mutant shed light on the different impacts of S130 in the binding of vaborbactam versus avibactam, another recently approved β-lactamase inhibitor. Taken together, these new data provide valuable insights into the inhibition mechanism of vaborbactam and future development of cyclic boronate inhibitors., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
34. An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques.
- Author
-
Powell RL, Weiss S, Fox A, Liu X, Itri V, Jiang X, Luo CC, Spencer DA, Pandey S, Cheever T, Fuller DH, Totrov M, Hessell AJ, Haigwood NL, Kong XP, and Zolla-Pazner S
- Subjects
- Animals, Antibody Formation, Disease Models, Animal, HIV Antigens genetics, HIV Envelope Protein gp120 genetics, HIV Envelope Protein gp120 immunology, HIV Infections immunology, HIV Infections prevention & control, Immunization, Immunogenicity, Vaccine immunology, Viral Envelope Proteins genetics, AIDS Vaccines immunology, HIV Antibodies immunology, HIV Antigens immunology, HIV-1 immunology, Immunoglobulin Fc Fragments immunology, Macaca mulatta immunology, Viral Envelope Proteins immunology
- Abstract
The HIV vaccine field now recognizes the potential importance of generating polyfunctional antibodies (Abs). The only clinical HIV vaccine trial to date to show significant efficacy (RV144) found that reduced infection rates correlated with the level of nonneutralizing Abs specific for the V2 region of the envelope glycoprotein. We have conducted a comprehensive preclinical reverse vaccinology-based vaccine program that has included the design and production and testing of numerous scaffolded V2 region immunogens. The most immunogenic vaccine regimen in nonhuman primates among those studied as part of this program consisted of a cocktail of three immunogens presenting V2 from different viruses and clades in the context of different scaffolds. Presently we demonstrate that the V2-specific Ab response from this regimen was highly durable and functionally diverse for the duration of the study (25 weeks after the final immunization). The total IgG binding response at this late time point exhibited only an ∼5× reduction in potency. Three immunizations appeared essential for the elicitation of a strong Ab-dependent cellular cytotoxicity (ADCC) response for all animals, as opposed to the Ab-dependent cellular phagocytosis (ADCP) and virus capture responses, which were comparably potent after only 2 immunizations. All functionalities measured were highly durable through the study period. Therefore, testing this vaccine candidate for its protective capacity is warranted. IMPORTANCE The only HIV vaccine trial for which protective efficacy was detected correlated this efficacy with V2-specific Abs that were effectively nonneutralizing. This result has fueled a decade of HIV vaccine research focused on designing an HIV vaccine capable of eliciting V2-focused, polyfunctional Abs that effectively bind HIV and trigger various leukocytes to kill the virus and restrict viral spread. From the numerous vaccine candidates designed and tested as part of our V2-focused preclinical vaccine program, we have identified immunogens and a vaccine regimen that induces a highly durable and polyfunctional V2-focused Ab response in rhesus macaques, described herein., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
35. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
- Author
-
Hecker SJ, Reddy KR, Lomovskaya O, Griffith DC, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Parkinson J, Totrov M, Boyer SH, Glinka TW, Pemberton OA, Chen Y, and Dudley MN
- Subjects
- Animals, Bacteria drug effects, Borinic Acids chemistry, Borinic Acids pharmacokinetics, Borinic Acids therapeutic use, Boronic Acids chemistry, Boronic Acids pharmacokinetics, Boronic Acids therapeutic use, Carboxylic Acids chemistry, Carboxylic Acids pharmacokinetics, Carboxylic Acids therapeutic use, Drug Discovery, Klebsiella Infections drug therapy, Mice, Microbial Sensitivity Tests, Structure-Activity Relationship, beta-Lactamase Inhibitors chemistry, beta-Lactamase Inhibitors pharmacokinetics, beta-Lactamase Inhibitors therapeutic use, Borinic Acids pharmacology, Boronic Acids pharmacology, Carboxylic Acids pharmacology, beta-Lactamase Inhibitors pharmacology
- Abstract
Despite major advances in the β-lactamase inhibitor field, certain enzymes remain refractory to inhibition by agents recently introduced. Most important among these are the class B (metallo) enzyme NDM-1 of Enterobacteriaceae and the class D (OXA) enzymes of Acinetobacter baumannii . Continuing the boronic acid program that led to vaborbactam, efforts were directed toward expanding the spectrum to allow treatment of a wider range of organisms. Through key structural modifications of a bicyclic lead, stepwise gains in spectrum of inhibition were achieved, ultimately resulting in QPX7728 ( 35 ). This compound displays a remarkably broad spectrum of inhibition, including class B and class D enzymes, and is little affected by porin modifications and efflux. Compound 35 is a promising agent for use in combination with a β-lactam antibiotic for the treatment of a wide range of multidrug resistant Gram-negative bacterial infections, by both intravenous and oral administration.
- Published
- 2020
- Full Text
- View/download PDF
36. Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases.
- Author
-
Lomovskaya O, Tsivkovski R, Nelson K, Rubio-Aparicio D, Sun D, Totrov M, and Dudley MN
- Subjects
- Microbial Sensitivity Tests, Monobactams, Serine, beta-Lactamases genetics, Anti-Bacterial Agents pharmacology, beta-Lactamase Inhibitors pharmacology
- Abstract
QPX7728 is an ultrabroad-spectrum boronic acid beta-lactamase inhibitor, with potent inhibition of key serine and metallo-beta-lactamases being observed in biochemical assays. Microbiological studies using characterized strains were used to provide a comprehensive characterization of the spectrum of beta-lactamase inhibition by QPX7728. The MICs of multiple antibiotics administered intravenously only (ceftazidime, piperacillin, cefepime, ceftolozane, and meropenem) and orally bioavailable antibiotics (ceftibuten, cefpodoxime, tebipenem) alone and in combination with QPX7728 (4 μg/ml), as well as comparator agents, were determined against panels of laboratory strains of Pseudomonas aeruginosa and Klebsiella pneumoniae expressing over 55 diverse serine and metallo-beta-lactamases. QPX7728 significantly enhanced the potency of antibiotics against strains expressing class A extended-spectrum beta-lactamases (CTX-M, SHV, TEM, VEB, PER) and carbapenemases (KPC, SME, NMC-A, BKC-1), consistent with the beta-lactamase inhibition demonstrated in biochemical assays. It also inhibited both plasmidic (CMY, FOX, MIR, DHA) and chromosomally encoded (P99, PDC, ADC) class C beta-lactamases and class D enzymes, including carbapenemases, such as OXA-48 from Enterobacteriaceae and OXA enzymes from Acinetobacter baumannii (OXA-23/24/72/58). QPX7728 is also a potent inhibitor of many class B metallo-beta-lactamases (NDM, VIM, CcrA, IMP, and GIM but not SPM or L1). Addition of QPX7728 (4 μg/ml) reduced the MICs for a majority of the strains to the level observed for the control with the vector alone, indicative of complete beta-lactamase inhibition. The ultrabroad-spectrum beta-lactamase inhibition profile makes QPX7728 a viable candidate for further development., (Copyright © 2020 Lomovskaya et al.)
- Published
- 2020
- Full Text
- View/download PDF
37. Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases.
- Author
-
Tsivkovski R, Totrov M, and Lomovskaya O
- Subjects
- Anti-Bacterial Agents pharmacology, Microbial Sensitivity Tests, Monobactams, beta-Lactamases genetics, Serine, beta-Lactamase Inhibitors pharmacology
- Abstract
QPX7728 is a new ultrabroad-spectrum inhibitor of serine and metallo-beta-lactamases (MBLs) from a class of cyclic boronates that gave rise to vaborbactam. The spectrum and mechanism of beta-lactamase inhibition by QPX7728 were assessed using purified enzymes from all molecular classes. QPX7728 inhibits class A extended-spectrum beta-lactamases (ESBLs) (50% inhibitory concentration [IC
50 ] range, 1 to 3 nM) and carbapenemases such as KPC (IC50 , 2.9 ± 0.4 nM) as well as class C P99 (IC50 of 22 ± 8 nM) with a potency that is comparable to or higher than recently FDA-approved beta-lactamase inhibitors (BLIs) avibactam, relebactam, and vaborbactam. Unlike those other BLIs, QPX7728 is also a potent inhibitor of class D carbapenemases such as OXA-48 from Enterobacteriaceae and OXA enzymes from Acinetobacter baumannii (OXA-23/24/58, IC50 range, 1 to 2 nM) as well as MBLs such as NDM-1 (IC50 , 55 ± 25 nM), VIM-1 (IC50 , 14 ± 4 nM), and IMP-1 (IC50 , 610 ± 70 nM). Inhibition of serine enzymes by QPX7728 is associated with progressive inactivation with a high-efficiency k2 / K ranging from 6.3 × 104 M5 M-1 s-1 , ∼50 min for OXA-48, and 2 to 3 h for KPC and CTX-M-15. QPX7728 inhibited all tested serine enzymes at a 1:1 molar ratio. Metallo-beta-lactamases NDM, VIM, and IMP were inhibited by a competitive mechanism with fast-on-fast-off kinetics, with A. baumannii , ∼50 min for OXA-48, and 2 to 3 h for KPC and CTX-M-15. QPX7728 inhibited all tested serine enzymes at a 1:1 molar ratio. Metallo-beta-lactamases NDM, VIM, and IMP were inhibited by a competitive mechanism with fast-on-fast-off kinetics, with Ki s of 7.5 ± 2.1 nM, 32 ± 14 nM, and 240 ± 30 nM for VIM-1, NDM-1, and IMP-1, respectively. QPX7728's ultrabroad spectrum of BLI inhibition combined with its high potency enables combinations with multiple different beta-lactam antibiotics., (Copyright © 2020 Tsivkovski et al.)- Published
- 2020
- Full Text
- View/download PDF
38. Macrocycle modeling in ICM: benchmarking and evaluation in D3R Grand Challenge 4.
- Author
-
Lam PC, Abagyan R, and Totrov M
- Subjects
- Benchmarking, Binding Sites drug effects, Computer-Aided Design, Crystallography, X-Ray, Databases, Protein, Humans, Ligands, Macrocyclic Compounds therapeutic use, Protein Binding drug effects, Protein Conformation drug effects, Quantitative Structure-Activity Relationship, Drug Design, Macrocyclic Compounds chemistry, Proteins chemistry, Thermodynamics
- Abstract
Macrocycles represent a potentially vast extension of drug chemical space still largely untapped by synthetic compounds. Sampling of flexible rings is incorporated in the ICM-dock protocol. We tested the ability of ICM-dock to reproduce macrocyclic ligand-protein receptor complexes, first in a large retrospective benchmark (246 complexes), and next, in context of the D3R Grand Challenge 4 (GC4), where we modeled bound complexes and predicted activities for a series of macrocyclic BACE inhibitors. Sub-angstrom accuracy was achieved in ligand pose prediction both in cross-docking (D3R Challenge Stage 1A) and cognate (Stage 1B) setup. Stage 1B submission was top ranked by mean and average RMSDs, even though no ligand knowledge was used in our simulations on this Stage. Furthermore, we demonstrate successful receptor conformational selection in Stage 1A, aided by the enhanced '4D' multiple receptor conformation docking protocol with optimized scoring offsets. In the activity 3D QSAR modeling, predictivity of the BACE pKd model was modest, while for the second target (Cathepsin-S), leading performance was achieved. Difference in activity prediction performance between the targets is likely explained by the amount of available and relevant training data.
- Published
- 2019
- Full Text
- View/download PDF
39. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.
- Author
-
Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, Cheever T, Fuller DH, Park B, Krebs SJ, Totrov M, Haigwood NL, Kong XP, and Zolla-Pazner S
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Antibody Affinity immunology, Cell Line, Exudates and Transudates, Female, Humans, Immunization, Macaca mulatta, Male, Mucous Membrane immunology, Vagina immunology, Vagina virology, AIDS Vaccines immunology, Antibody Formation immunology, Epitopes immunology, HIV Infections immunology, Protein Multimerization, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
The V1V2 region of the HIV-1 envelope is the target of several broadly neutralizing antibodies (bNAbs). Antibodies to V1V2 elicited in the RV144 clinical trial correlated with a reduced risk of HIV infection, but these antibodies were without broad neutralizing activity. Antibodies targeting V1V2 also correlated with a reduced viral load in immunized macaques challenged with simian immunodeficiency virus (SIV) or simian/human immunodeficiency virus (SHIV). To focus immune responses on V1V2, we engrafted the native, glycosylated V1V2 domain onto five different multimeric scaffold proteins and conducted comparative immunogenicity studies in macaques. Vaccinated macaques developed high titers of plasma and mucosal antibodies that targeted structurally distinct V1V2 epitopes. Plasma antibodies displayed limited neutralizing activity but were functionally active for ADCC and phagocytosis, which was detectable 1-2 years after immunizations ended. This study demonstrates that multivalent, glycosylated V1V2-scaffold protein immunogens focus the antibody response on V1V2 and are differentially effective at inducing polyfunctional antibodies with characteristics associated with protection., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
40. Mosquito Acetylcholinesterase as a Target for Novel Phenyl-Substituted Carbamates.
- Author
-
Mutunga JM, Ma M, Chen QH, Hartsel JA, Wong DM, Ding S, Totrov M, Carlier PR, and Bloomquist JR
- Subjects
- Animals, Cholinesterase Inhibitors chemistry, Female, Humans, Phenylcarbamates chemistry, Structure-Activity Relationship, Acetylcholinesterase drug effects, Anopheles enzymology, Cholinesterase Inhibitors pharmacology, Insecticides pharmacology, Phenylcarbamates pharmacology
- Abstract
New insecticides are needed for control of disease-vectoring mosquitoes and this research evaluates the activity of new carbamate acetylcholinesterase (AChE) inhibitors. Biochemical and toxicological characterization of carbamates based on the parent structure of terbam, 3- tert -butylphenyl methylcarbamate, was performed. In vitro enzyme inhibition selectivity ( Anopheles gambiae versus human) was assessed by the Ellman assay, as well as the lethality to whole insects by the World Health Organization (WHO) paper contact assay. Bromination at the phenyl C6 position increased inhibitory potency to both AChEs, whereas a 6-iodo substituent led to loss of potency, and both halogenations caused a significant reduction of mosquitocidal activity. Similarly, installation of a hexyl substituent at C6 drastically reduced inhibition of Ag AChE, but showed a smaller reduction in the inhibition of hAChE. A series of 4-carboxamido analogs of the parent compound gave reduced activity against Ag AChE and generally showed more activity against hAChE than Ag AChE. Replacement of the 3- t -buyl group with CF
3 resulted in poor anticholinesterase activity, but this compound did have measurable mosquitocidal activity. A series of methyl- and fluoro- analogs of 3-trialkylsilyl compounds were also synthesized, but unfortunately resulted in disappointing activity. Finally, a series of sulfenylated proinsecticides showed poor paper contact toxicity, but one of them had topical activity against adult female Anopheles gambiae . Overall, the analogs prepared here contributed to a better understanding of carbamate structure-activity relationships (SAR), but no new significant leads were generated.- Published
- 2019
- Full Text
- View/download PDF
41. Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.
- Author
-
Liu L, Li L, Nanfack A, Mayr LM, Soni S, Kohutnicki A, Agyingi L, Wang XH, Tuen M, Shao Y, Totrov M, Zolla-Pazner S, Kong XP, Duerr R, and Gorny MK
- Subjects
- AIDS Vaccines immunology, Cameroon epidemiology, HIV Antibodies immunology, HIV Antigens immunology, HIV Infections epidemiology, HIV Infections prevention & control, Humans, Multivariate Analysis, Viral Load, HIV Antibodies blood, HIV Infections immunology, HIV Infections virology, HIV-1
- Abstract
The results of the RV144 vaccine clinical trial showed a correlation between high level of anti-V1V2 antibodies (Abs) and a decreased risk of acquiring HIV-1 infection. This turned the focus of HIV vaccine design to the induction of elevated levels of anti-V2 Abs to increase vaccine efficacy. In plasma samples from HIV-1 infected Cameroonian individuals, we observed broad variations in levels of anti-V2 Abs, and 6 of the 79 plasma samples tested longitudinally displayed substantial deficiency of V2 Abs. Sequence analysis of the V2 region from plasma viruses and multivariate analyses of V2 characteristics showed a significant difference in several features between V2-deficient and V2-reactive plasma Abs. These results suggest that HIV vaccine immunogens containing a shorter V2 region with fewer glycosylation sites and higher electrostatic charges can be beneficial for induction of a higher level of anti-V2 Abs and thus contribute to HIV vaccine efficacy., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. Hybrid receptor structure/ligand-based docking and activity prediction in ICM: development and evaluation in D3R Grand Challenge 3.
- Author
-
Lam PC, Abagyan R, and Totrov M
- Subjects
- Binding Sites, Computer-Aided Design, Crystallography, X-Ray, Databases, Protein, Drug Design, Ligands, Machine Learning, Protein Binding, Protein Conformation, Quantitative Structure-Activity Relationship, Thermodynamics, Cathepsins chemistry, Molecular Docking Simulation methods
- Abstract
In context of D3R Grand Challenge 3 we have investigated several ligand activity prediction protocols that combined elements of a physics-based energy function (ICM VLS score) and the knowledge-based Atomic Property Field 3D QSAR approach. Activity prediction models utilized poses produced by ICM-Dock with ligand bias and 4D receptor conformational ensembles (LigBEnD). Hybrid APF/P (APF/Physics) models were superior to pure physics- or knowledge-based models in our preliminary tests using rigorous three-fold clustered cross-validation and later proved successful in the blind prediction for D3R GC3 sets, consistently performing well across four different targets. The results demonstrate that knowledge-based and physics-based inputs into the machine-learning activity model can be non-redundant and synergistic.
- Published
- 2019
- Full Text
- View/download PDF
43. Select β- and γ-branched 1-alkylpyrazol-4-yl methylcarbamates exhibit high selectivity for inhibition of Anopheles gambiae versus human acetylcholinesterase.
- Author
-
Carlier PR, Chen QH, Verma A, Wong DM, Mutunga JM, Müller J, Islam R, Shimozono AM, Tong F, Li J, Totrov M, and Bloomquist JR
- Subjects
- Acetylcholinesterase metabolism, Animals, Anopheles physiology, Carbamates chemistry, Cholinesterase Inhibitors chemistry, Female, Humans, Insecticide Resistance genetics, Insecticides chemistry, Models, Molecular, Mutation, Anopheles drug effects, Carbamates toxicity, Cholinesterase Inhibitors toxicity, Insecticides toxicity
- Abstract
The widespread emergence of pyrethroid-resistant Anopheles gambiae has intensified the need to find new contact mosquitocides for indoor residual spraying and insecticide treated nets. With the goal of developing new species-selective and resistance-breaking acetylcholinesterase (AChE)-inhibiting mosquitocides, in this report we revisit the effects of carbamate substitution on aryl carbamates, and variation of the 1-alkyl group on pyrazol-4-yl methylcarbamates. Compared to aryl methylcarbamates, aryl dimethylcarbamates were found to have lower selectivity for An. gambiae AChE ( Ag AChE) over human AChE (hAChE), but improved tarsal contact toxicity to G3 strain An. gambiae . Molecular modeling studies suggest the lower species-selectivity of the aryl dimethylcarbamates can be attributed to a less flexible acyl pocket in Ag AChE relative to hAChE. The improved tarsal contact toxicity of the aryl dimethylcarbamates relative to the corresponding methylcarbamates is attributed to a range of complementary phenomena. With respect to the pyrazol-4-yl methylcarbamates, the previously observed low An. gambiae -selectivity of compounds bearing α-branched 1-alkyl groups was improved by employing β- and γ-branched 1-alkyl groups. Compounds 22a (cyclopentylmethyl), 21a (cyclobutylmethyl), and 26a (3-methylbutyl) offer 250-fold, 120-fold, and 96-fold selectivity, respectively, for inhibition of Ag AChE vs. hAChE. Molecular modeling studies suggests the high species-selectivity of these compounds can be attributed to the greater mobility of the W84 side chain in the choline-binding site of Ag AChE, compared to that of W86 in hAChE. Compound 26a has reasonable contact toxicity to G3 strain An. gambiae (LC
50 = 269 μg/mL) and low cross-resistance to Akron strain (LC50 = 948 μg/mL), which bears the G119S resistance mutation., Competing Interests: Conflict of Interest: None of the authors have any conflict to report.- Published
- 2018
- Full Text
- View/download PDF
44. Protein-RNA Docking Using ICM.
- Author
-
Arnautova YA, Abagyan R, and Totrov M
- Subjects
- Binding Sites, Protein Binding, Static Electricity, Algorithms, Computational Biology, RNA chemistry
- Abstract
Protein-RNA interactions play an important role in many biological processes. Computational methods such as docking have been developed to complement existing biophysical and structural biology techniques. Computational prediction of protein-RNA complex structures includes two steps: generating candidate structures from the individual protein and RNA parts and scoring the generated poses to pick out the correct one. In this work, we considered three recently developed data sets of protein-RNA complexes to evaluate and improve the performance of the FFT-based rigid-body docking algorithm implemented in the ICM package. An electrostatic term describing interactions between negatively charged phosphate groups and positively charged protein residues was added to the energy function used during the docking step to take into account the greater role that electrostatic interactions play in protein-RNA complexes. Next, the docking results were used to optimize a scoring function including van der Waals, electrostatic, and solvation terms. This optimization yielded a much smaller weight for the solvation term indicating that solvation energy may be less important for the scoring of protein-RNA structures. Rescoring of the generated poses with the new scoring function led to much higher success rates, while pose clustering by contact fingerprints produced further improvements, achieving a success rate of 0.66 for the top 100 structures.
- Published
- 2018
- Full Text
- View/download PDF
45. Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.
- Author
-
Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, Totrov M, Kong XP, Fiore-Gartland AJ, Haigwood NL, Zolla-Pazner S, and Hioe CE
- Subjects
- AIDS Vaccines standards, Clinical Trials, Phase III as Topic, Cytotoxicity, Immunologic, Epitopes chemistry, Epitopes immunology, HIV Envelope Protein gp120 chemistry, Humans, Phagocytosis, AIDS Vaccines immunology, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology
- Abstract
Immunization with HIV AIDSVAX gp120 vaccines in the phase III VAX003 and VAX004 trials did not confer protection. To understand the shortcomings in antibody (Ab) responses induced by these vaccines, we evaluated the kinetics of Ab responses to the V1V2 and V3 regions of gp120 and the induction of Ab-mediated antiviral functions during the course of 7 vaccinations over a 30.5-month period. Plasma samples from VAX003 and VAX004 vaccinees and placebo recipients were measured for ELISA-binding Abs and for virus neutralization, Ab-dependent cellular phagocytosis (ADCP), and Ab-dependent cellular cytotoxicity (ADCC). Ab responses to V1V2 and V3 peaked after 3 to 4 immunizations and declined after 5 to 7 immunizations. The deteriorating responses were most evident against epitopes in the underside of the V1V2 β-barrel and in the V3 crown. Correspondingly, vaccinees demonstrated higher neutralization against SF162 pseudovirus sensitive to anti-V1V2 and anti-V3 Abs after 3 or 4 immunizations than after 7 immunizations. Higher levels of ADCP and ADCC were also observed at early or mid-time points as compared with the final time point. Hence, VAX003 and VAX004 vaccinees generated V1V2- and V3-binding Abs and functional Abs after 3 to 4 immunizations, but subsequent boosts did not maintain these responses.
- Published
- 2018
- Full Text
- View/download PDF
46. Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach.
- Author
-
Lam PC, Abagyan R, and Totrov M
- Subjects
- Algorithms, Binding Sites, Computer-Aided Design, Databases, Protein, Drug Design, Drug Discovery, Humans, Ligands, Protein Binding, Protein Conformation, Receptors, Cytoplasmic and Nuclear chemistry, Small Molecule Libraries chemistry, Small Molecule Libraries pharmacology, Software, Molecular Docking Simulation, Receptors, Cytoplasmic and Nuclear metabolism
- Abstract
Ligand docking to flexible protein molecules can be efficiently carried out through ensemble docking to multiple protein conformations, either from experimental X-ray structures or from in silico simulations. The success of ensemble docking often requires the careful selection of complementary protein conformations, through docking and scoring of known co-crystallized ligands. False positives, in which a ligand in a wrong pose achieves a better docking score than that of native pose, arise as additional protein conformations are added. In the current study, we developed a new ligand-biased ensemble receptor docking method and composite scoring function which combine the use of ligand-based atomic property field (APF) method with receptor structure-based docking. This method helps us to correctly dock 30 out of 36 ligands presented by the D3R docking challenge. For the six mis-docked ligands, the cognate receptor structures prove to be too different from the 40 available experimental Pocketome conformations used for docking and could be identified only by receptor sampling beyond experimentally explored conformational subspace.
- Published
- 2018
- Full Text
- View/download PDF
47. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
- Author
-
Powell RLR, Totrov M, Itri V, Liu X, Fox A, and Zolla-Pazner S
- Subjects
- Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology, Binding Sites, HEK293 Cells, HIV Envelope Protein gp120 genetics, HIV Infections virology, HIV-1, Humans, Neutralization Tests, Protein Binding, Epitopes immunology, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology
- Abstract
We recently showed that mutations in the HIV-1 envelope (Env) destabilize the V3 loop, rendering neutralization-resistant viruses sensitive to V3-directed monoclonal antibodies (MAbs). Here, we investigated the propagation of this effect on other Env epitopes, with special emphasis on V2 loop exposure. Wild-type JR-FL and 19 mutant JR-FL pseudoviruses were tested for neutralization sensitivity to 21 MAbs specific for epitopes in V2, the CD4 binding site (CD4bs), and the CD4-induced (CD4i) region. Certain glycan mutants, mutations in the gp120 hydrophobic core, and mutations in residues involved in intraprotomer interactions exposed epitopes in the V2i region (which overlies the α4β7 integrin binding site) and the V3 crown, suggesting general destabilization of the distal region of the trimer apex. In contrast, other glycan mutants, mutations affecting interprotomer interactions, and mutations affecting the CD4bs exposed V3 but not V2i epitopes. These data indicate for the first time that V3 can move independently of V2, with V3 pivoting out from its "tucked" position in the trimer while apparently leaving the V2 apex intact. Notably, none of the mutations exposed V2 epitopes without also exposing V3, suggesting that movement of V2 releases V3. Most mutations increased sensitivity to CD4bs-directed MAbs without exposure of the CD4i epitope, implying these mutations facilitate the trimers' maintenance of an intermediate energy state between open and closed conformations. Taken together, these data indicate that several transient Env epitopes can be rendered more accessible to antibodies (Abs) via specific mutations, and this may facilitate the design of V1V2-targeting immunogens. IMPORTANCE Many epitopes of the HIV envelope (Env) spike are relatively inaccessible to antibodies (Abs) compared to their exposure in the open Env conformation induced by receptor binding. However, the reduced infection rate that resulted from the vaccine used in the RV144 HIV-1 vaccine trial was correlated with the elicitation of V2- and V3-directed antibodies. Previously, we identified various mechanisms responsible for destabilizing the V3 loop; here, we determined, via mutation of numerous Env residues, which of these elements maintain the V1V2 loop in an inaccessible state and which expose V1V2 and/or V3 epitopes. Notably, our data indicate that V3 can move independently of V2, but none of the mutations studied expose V2 epitopes without also exposing V3. Additionally, V1V2 can be rendered more accessible to Abs via specific mutations, facilitating the development of engineered V2 immunogens., (Copyright © 2017 American Society for Microbiology.)
- Published
- 2017
- Full Text
- View/download PDF
48. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.
- Author
-
Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, and Hioe CE
- Subjects
- AIDS Vaccines administration & dosage, Animals, Antibodies, Neutralizing blood, Antibodies, Neutralizing chemistry, Antibodies, Neutralizing metabolism, Crystallography, X-Ray, HIV Antibodies chemistry, HIV Antibodies metabolism, HIV Antigens chemistry, HIV Antigens metabolism, Humans, Macaca, Mice, Protein Binding, Protein Conformation, Rabbits, env Gene Products, Human Immunodeficiency Virus chemistry, env Gene Products, Human Immunodeficiency Virus metabolism, AIDS Vaccines immunology, HIV Antibodies blood, HIV Antigens immunology, HIV Infections immunology, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
The V3 loop in the HIV envelope gp120 is one of the immunogenic sites targeted by Abs. The V3 crown in particular has conserved structural elements recognized by cross-reactive neutralizing Abs, indicating its potential contribution in protection against HIV. Crystallographic analyses of anti-V3 crown mAbs in complex with the V3 peptides have revealed that these mAbs recognize the conserved sites on the V3 crown via two distinct strategies: a cradle-binding mode (V3C) and a ladle-binding (V3L) mode. However, almost all of the anti-V3 crown mAbs studied in the past were isolated from chronically HIV-infected individuals. The extents to which the two types of anti-V3 crown Abs are generated by vaccination are unknown. This study analyzed the prevalence of V3C-type and V3L-type Ab responses in HIV-infected individuals and in HIV envelope-immunized humans and animals using peptide mimotopes that distinguish the two Ab types. The results show that both V3L-type and V3C-type Abs were generated by the vast majority of chronically HIV-infected humans, although the V3L-type were more prevalent. In contrast, only one of the two V3 Ab types was elicited in vaccinated humans or animal models, irrespective of HIV-1 envelope clades, envelope constructs (oligomeric or monomeric), and protocols (DNA plus protein or protein alone) used for vaccinations. The V3C-type Abs were produced by vaccinated humans, macaques, and rabbits, whereas the V3L-type Abs were made by mice. The V3C-type and V3L-type Abs generated by the vaccinations were able to mediate virus neutralization. These data indicate the restricted repertoires and the species-specific differences in the functional V3-specific Ab responses induced by the HIV envelope vaccines. The study implies the need for improving immunogen designs and vaccination strategies to broaden the diversity of Abs in order to target the different conserved epitopes in the V3 loop and, by extension, in the entire HIV envelope., (Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
49. Discovery of Species-selective and Resistance-breaking Anticholinesterase Insecticides for the Malaria Mosquito.
- Author
-
Carlier PR, Bloomquist JR, Totrov M, and Li J
- Subjects
- Acetylcholinesterase chemistry, Acetylcholinesterase genetics, Animals, Anopheles drug effects, Carbamates chemistry, Carbamates metabolism, Carbamates toxicity, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors toxicity, Drug Discovery, Drug Resistance drug effects, Humans, Insect Vectors drug effects, Insecticides chemistry, Insecticides metabolism, Insecticides toxicity, Ketones chemistry, Ketones metabolism, Species Specificity, Acetylcholinesterase metabolism, Cholinesterase Inhibitors metabolism
- Abstract
Great reductions in malaria mortality have been accomplished in the last 15 years, in part due to the widespread roll-out of insecticide-treated bednets across sub-Saharan Africa. To date, these nets only employ pyrethroids, insecticides that target the voltage-gated sodium ion channel of the malaria vector, Anopheles gambiae. Due to the growing emergence of An. gambiae strains that are resistant to pyrethroids, there is an urgent need to develop new public health insecticides that engage a different target and possess low mammalian toxicity. In this review, we will describe efforts to develop highly species-specific and resistance-breaking inhibitors of An. gambiae acetylcholinesterase (AgAChE). These efforts have been greatly aided by advances in knowledge of the structure of the enzyme, and two major inhibitor design strategies have been explored. Since AgAChE possesses an unpaired Cys residue not present in mammalian AChE, a logical strategy to achieve selective inhibition involves design of compounds that could ligate that Cys. A second strategy involves the design of new molecules to target the catalytic serine of the enzyme. Here the challenge is not only to achieve high inhibition selectivity vs human AChE, but also to demonstrate toxicity to An. gambiae that carry the G119S resistance mutation of AgAChE. The advances made and challenges remaining will be presented. This review is part of the special issue "Insecticide Mode of Action: From Insect to Mammalian Toxicity"., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2017
- Full Text
- View/download PDF
50. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
- Author
-
Jiang X, Totrov M, Li W, Sampson JM, Williams C, Lu H, Wu X, Lu S, Wang S, Zolla-Pazner S, and Kong XP
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines biosynthesis, AIDS Vaccines genetics, Amino Acid Sequence, Animals, Antibodies, Monoclonal biosynthesis, Antibodies, Neutralizing biosynthesis, Cross Reactions, Drug Design, Epitopes chemistry, Epitopes immunology, Female, Gene Expression, HIV Envelope Protein gp120 biosynthesis, HIV Envelope Protein gp120 genetics, HIV Infections immunology, HIV Infections virology, HIV-1 chemistry, HIV-1 genetics, HIV-1 immunology, Humans, Models, Molecular, Peptide Mapping, Phagocytosis drug effects, Protein Binding, Protein Structure, Secondary, Rabbits, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, AIDS Vaccines immunology, HIV Antibodies biosynthesis, HIV Envelope Protein gp120 immunology, HIV Infections prevention & control, Immunization, Secondary, Immunogenicity, Vaccine
- Abstract
The V1V2 region of HIV-1 gp120 harbors a major vulnerable site targeted by a group of broadly neutralizing monoclonal antibodies (MAbs) such as PG9 through strand-strand recognition. However, this epitope region is structurally polymorphic as it can also form a helical conformation recognized by RV144 vaccine-induced MAb CH58. This structural polymorphism is a potential mechanism for masking the V1V2 vulnerable site. Designing immunogens that can induce conformation-specific antibody (Ab) responses may lead to vaccines targeting this vulnerable site. We designed a panel of immunogens engrafting the V1V2 domain into trimeric and pentameric scaffolds in structurally constrained conformations. We also fused V1V2 to an Fc fragment to mimic the unconstrained V1V2 conformation. We tested these V1V2-scaffold proteins for immunogenicity in rabbits and assessed the responses by enzyme-linked immunosorbent assay (ELISA) and competition assays. Our V1V2 immunogens induced distinct conformation-specific Ab responses. Abs induced by structurally unconstrained immunogens reacted preferentially with unconstrained V1V2 antigens, suggesting recognition of the helical configuration, while Abs induced by the structurally constrained immunogens reacted preferentially with constrained V1V2 antigens, suggesting recognition of the β-strand conformation. The Ab responses induced by the structurally constrained immunogens were more broadly reactive and had higher titers than those induced by the structurally unconstrained immunogens. Our results demonstrate that immunogens presenting the different structural conformations of the gp120 V1V2 vulnerable site can be designed and that these immunogens induce distinct Ab responses with epitope conformation specificity. Therefore, these structurally constrained V1V2 immunogens are vaccine prototypes targeting the V1V2 domain of the HIV-1 envelope., Importance: The correlates analysis of the RV144 HIV-1 vaccine trial suggested that the presence of antibodies to the V1V2 region of HIV-1 gp120 was responsible for the modest protection observed in the trial. In addition, V1V2 harbors one of the key vulnerable sites of HIV-1 Env recognized by a family of broadly neutralizing MAbs such as PG9. Thus, V1V2 is a key target for vaccine development. However, this vulnerable site is structurally polymorphic, and designing immunogens that present different conformations is crucial for targeting this site. We show here that such immunogens can be designed and that they induced conformation-specific antibody responses in rabbits. Our immunogens are therefore prototypes of vaccine candidates targeting the V1V2 region of HIV-1 Env., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.